COMP <GO>
BHC vs NRIX // RSI-14 & 200D SMA MOMENTUM
Bausch Health Companies Inc. (NYSE) VS. Nurix Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BHC 7
— NRIX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BHC
LAST: $8.02 (-2.19%) • MKT CAP: $3.07B
rsi-technicals
64.8
LAST: $25.70 (-4.10%) • MKT CAP: $2.93B
rsi-technicals
62.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. NRIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BHC | NRIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.60% | -35.00% | +42.60 | BHC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 22.00% | -8.89% | +30.89 | BHC | /fcf-yield <GO> |
| Operating Margin | 17.70% | -60.00% | +77.70 | BHC | /operating-margins <GO> |
| Net Profit Margin | 1.50% | -60.00% | +61.50 | BHC | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 54.00% | -47.30 | NRIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 9.52 | -9.07 | NRIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 3/9 | +6.00 | BHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 64.8 | 62.3 | +2.50 | BHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.07B | $2.93B | $141.1M | BHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BHC REV | NRIX REV | BHC GROSS % | NRIX GROSS % | BHC FCF | NRIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.27B | $84.0M | — | — | $1.00B | -$263.5M |
| FY 2024 | $9.63B | $54.5M | — | — | $1.26B | -$181.9M |
| FY 2023 | $8.76B | $77.0M | — | — | $637.9M | -$81.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
NRIX // BETA —